Dr. Falk Pharma and Renexxion Align on Naronapride Trials
The companies have reached agreement with FDA and EMA regulators on a global Phase 3 clinical trial design for naronapride.
Updated on Oct. 21, 2026 in Diabetes

Live Poll
Do you believe pharmaceutical companies are making enough progress in developing effective long-term treatments for chronic conditions?
Dr. Falk Pharma and Renexxion have secured regulatory alignment from the FDA and EMA for a Phase 3 clinical trial program targeting diabetic and idiopathic gastroparesis. This approval includes the authorization to conduct NDA-enabling studies alongside these upcoming trials.
Why it matters
The coordinated trial strategy aims to significantly streamline the development timeline for naronapride, addressing a critical unmet medical need for patients living with gastroparesis. Regulatory concurrence on trial endpoints ensures that the data collected will meet international standards for future drug approval applications.
Gastroparesis has a formal diagnosis rate of 22 per 100,000 people. Dr. Falk Pharma, which maintains a global workforce of 1,550 employees, will support the program following the successful completion of the MOVE-IT Phase 2b trial.
The players
Dr. Falk Pharma
This is a German pharmaceutical company based in Freiburg that specializes in research and treatment for gastrointestinal and metabolic disorders.
Renexxion
Headquartered in Roscrea, Ireland, this biopharmaceutical company focuses on developing therapies for high-unmet-need conditions within the gastrointestinal space.
FDA
The Food and Drug Administration is the U.S. federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
EMA
The European Medicines Agency is an agency of the European Union in charge of the evaluation and supervision of pharmaceutical products for use in the EU.
The details
The developers will utilize the ANMS-GCSI-DD tool to establish primary and key secondary endpoints across the planned global studies. This strategy follows the completion of End of Phase 2 meetings, which allowed the manufacturers to finalize their development roadmap with both American and European regulatory bodies.
Timeline
October 21, 2026: Companies announced regulatory alignment on the Phase 3 program.
First half of 2027: Planned initiation of the global Phase 3 clinical trial program.
The Big Picture
This program builds directly upon the established protocols of the MOVE-IT Phase 2b trial. The move shifts the development of naronapride from exploratory mid-stage investigation to a final, large-scale clinical assessment.
This progress provides a clearer timeline for the potential arrival of a new treatment option for those suffering from the chronic symptoms of diabetic gastroparesis. Patients should note that while this trial design is now established, the drug is not yet available for prescription or pharmacy purchase.
The takeaway
The successful alignment between manufacturers and regulators marks a crucial step toward bringing potential new therapies to market. Stakeholders should monitor for study enrollment updates as the global program approaches its planned launch in 2027.
What happens next
The companies are scheduled to initiate the global Phase 3 program during the first half of 2027.
Further reading
Learn more about advancements in metabolic care on our Diabetes page.
More information
Review the latest updates on the development process at the Dr. Falk Pharma corporate information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe pharmaceutical companies are making enough progress in developing effective long-term treatments for chronic conditions?







